NRIX
Nurix Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.77B
P/E Ratio
—
EPS
$-3.28
Beta
1.98
52W High
$22.50
52W Low
$8.20
50-Day MA
$15.80
200-Day MA
$14.04
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.
Fundamentals
| Revenue (TTM) | $71.78M |
| Gross Profit (TTM) | $-259.60M |
| EBITDA | $-307.31M |
| Operating Margin | -1479.00% |
| Return on Equity | -61.40% |
| Return on Assets | -31.50% |
| Revenue/Share (TTM) | $0.77 |
| Book Value | $4.65 |
| Price-to-Book | 3.55 |
| Price-to-Sales (TTM) | 24.61 |
| EV/Revenue | 17.04 |
| EV/EBITDA | -3.35 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -66.10% |
| Shares Outstanding | $103.41M |
| Float | $95.23M |
| % Insiders | 1.10% |
| % Institutions | 111.15% |
Historical Volatility
HV 10-Day
43.93%
HV 20-Day
43.85%
HV 30-Day
48.74%
HV 60-Day
44.49%
HV Rank
11.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($30.24 target)
5
Strong Buy12
BuyData last updated: 4/29/2026